Kane Biotech Inc. (CVE:KNE – Get Free Report) reached a new 52-week low on Tuesday . The stock traded as low as C$0.06 and last traded at C$0.06, with a volume of 202850 shares. The stock had previously closed at C$0.06.
Kane Biotech Stock Performance
The company has a market cap of C$8.64 million, a price-to-earnings ratio of 1.50 and a beta of 0.52. The company’s fifty day moving average price is C$0.09 and its two-hundred day moving average price is C$0.10. The company has a quick ratio of 0.39, a current ratio of 0.80 and a debt-to-equity ratio of -331.42.
About Kane Biotech
Kane Biotech Inc, a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections.
Further Reading
- Five stocks we like better than Kane Biotech
- What is a Dividend King?
- 2 Reasons Netflix’s 40% Rally Is Far From Over
- Top Stocks Investing in 5G Technology
- Boeing Landed New Deals With China and the Saudis for More Upside
- How to trade penny stocks: A step-by-step guide
- Hims & Hers Stock Chart Points to Strong Bullish Continuation
Receive News & Ratings for Kane Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kane Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
